title: Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1.
abstract: OBJECTIVE
  Hot flashes are a common problem for which effective and safe treatments are needed. The current trial was conducted on the basis of preliminary promising data that pregabalin decreased hot flashes.
  
  
  METHODS
  A double-blind, placebo-controlled, randomized trial design was used to compare pregabalin at target doses of 75 mg twice daily and 150 mg twice daily with a placebo. Hot flash frequencies and scores (frequency times mean severity) were recorded daily during a baseline week and for six treatment weeks. The primary end point for this study was the change-from-baseline hot flash score during treatment week 6 between the 150 mg twice daily target pregabalin treatment and placebo. Nonparametric Wilcoxon rank sum tests, two-sample t tests, and chi(2) tests were used to compare the primary and secondary hot flash efficacy end points between pregabalin treatments and placebo.
  
  
  RESULTS
  Hot flash score changes available for 163 patients during the sixth treatment week compared with a baseline week decreased by 50%, 65%, and 71% in the placebo, and target 75 mg twice daily and 150 mg twice daily pregabalin arms, respectively (P = .009 and P = .007, comparing respective pregabalin arms to the placebo arm). While some toxicities were significantly more common in the pregabalin arms, being more evident with the higher dose, pregabalin was generally well tolerated by most patients.
  
  
  CONCLUSIONS
  Pregabalin decreases hot flashes and is reasonably well tolerated. A target dose of 75 mg twice daily is recommended. Its effects appear to be roughly comparable to what has been reported with gabapentin and with some newer antidepressants.
authors.affiliation: Mayo Clinic Rochester, Rochester, MN 55905, USA. cloprinzi@mayo.edu
authors.forename: Charles L
authors.initials: CL
authors.lastname: Loprinzi
authors.forename: Rui
authors.initials: R
authors.lastname: Qin
authors.forename: Ernie P
authors.initials: EP
authors.lastname: Balcueva
authors.forename: Ernie P
authors.initials: EP
authors.lastname: Baclueva
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Flynn
authors.forename: Kendrith M
authors.initials: KM
authors.lastname: Rowland
authors.forename: David L
authors.initials: DL
authors.lastname: Graham
authors.forename: Nancy K
authors.initials: NK
authors.lastname: Erwin
authors.forename: Shaker R
authors.initials: SR
authors.lastname: Dakhil
authors.forename: Donald J
authors.initials: DJ
authors.lastname: Jurgens
authors.forename: Kelli N
authors.initials: KN
authors.lastname: Burger
mesh_terms: D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D019584:Hot Flashes / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D010919:Placebos; D017698:Postmenopause; D000069583:Pregabalin; D011379:Prognosis; D011788:Quality of Life; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D010919:Placebos; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid